Company intelligence / Profile preview
Apexian Pharmaceuticals
Indianapolis, Indiana, United Statesapexianpharma.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
APX3330 has completed Phase 2 trials for Diabetic Retinopathy/Diabetic Macular Edema with Ocuphire Pharma. It has been dosed twice-a-day in over 400 subjects across 11 Phase 1 and Phase 2 trials, with few systemic adverse events reported and clinical data supporting chronic administration[6][8].
- Therapeutic areas
- OphthalmologyOncologyGastroenterology
- Modalities
- Small molecule drugsChemical drugs
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Ocuphire Pharma
Beyond the preview
Go deeper on Apexian Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apexian Pharmaceuticals.